Bluejay Diagnostics, INC 10-Q quarterly reports

Bluejay Diagnostics reports increased R&D spending and continued net losses in its Q2 2026 filing, highlighting a critical need for further capital to fund operations through mid-2027.

Bluejay Diagnostics reports a net loss of $1.92 million for Q1 2026 and highlights substantial doubt about its ability to continue as a going concern, requiring at least $20 million in new capital by the end of 2027.

Bluejay Diagnostics reports continued net losses and substantial doubt about its ability to continue as a going concern, despite progress in clinical trials and recent capital raises.

Bluejay Diagnostics reports substantial doubt about its ability to continue as a going concern, needing immediate capital to avoid potential liquidation.

Bluejay Diagnostics' Q1 2025 results reveal a net loss of $1.86 million and highlight substantial doubt about the company's ability to continue as a going concern without securing significant additional funding.

Bluejay Diagnostics' Q3 2024 report reveals ongoing financial losses, manufacturing delays, and concerns about the company's ability to continue as a going concern.

Bluejay Diagnostics reported a net loss of $4.8 million for the six months ended June 30, 2024, and faces challenges related to its Nasdaq listing and going concern status.

Bluejay Diagnostics reported a net loss of $2.3 million for the first quarter of 2024 and faces significant financial challenges requiring imminent capital raising to continue operations.